In a significant development, the UK government has announced an indefinite ban on the use of puberty blockers for young individuals diagnosed with gender dysphoria, except within clinical trials. This decision extends the temporary ban that was implemented earlier in the year.
UK Government Enacts Permanent Ban on Puberty Blockers for Minors
UK Government Enacts Permanent Ban on Puberty Blockers for Minors
The indefinite suspension of puberty blockers for those under 18 aims to prioritize health and safety in treating gender dysphoria.
On December 11, 2024, Health Secretary Wes Streeting revealed that guidance from medical professionals highlighted serious safety concerns regarding the administration of puberty blockers to minors without comprehensive research on their effects. Mr. Streeting emphasized the need for caution in dealing with this vulnerable demographic, underscoring the commitment to uphold expert recommendations.
To address the lack of evidence surrounding these treatments, the government plans to initiate a clinical trial next year to build a solid foundation for the medical use of puberty blockers. This policy, applicable throughout England, Scotland, Wales, and Northern Ireland, follows earlier restrictions set by the previous Conservative government.
The National Health Service (NHS) suspended routine prescriptions of puberty blockers for those under 18 after a pivotal review led by pediatric expert Hilary Cass. In her report published in April, Cass asserted that the field of gender identity services lacks firm evidence, especially concerning hormone therapies that halt puberty or alter physical characteristics. This latest government stance reflects a broader reevaluation of youth treatment protocols in the UK.
To address the lack of evidence surrounding these treatments, the government plans to initiate a clinical trial next year to build a solid foundation for the medical use of puberty blockers. This policy, applicable throughout England, Scotland, Wales, and Northern Ireland, follows earlier restrictions set by the previous Conservative government.
The National Health Service (NHS) suspended routine prescriptions of puberty blockers for those under 18 after a pivotal review led by pediatric expert Hilary Cass. In her report published in April, Cass asserted that the field of gender identity services lacks firm evidence, especially concerning hormone therapies that halt puberty or alter physical characteristics. This latest government stance reflects a broader reevaluation of youth treatment protocols in the UK.
